Incyte Corporation
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- William J. Meury
- Full Time Employees
- 2,617
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 1801 Augustine Cut-Off Wilmington DE United States of America 19803
- IPO Date
- Nov 4, 1993
- CIK
- 0000879169
- Website
- incyte.com
- Similar Companies
- Business
- Incyte Corporation (INCY) is a Wilmington, Delaware-based biopharmaceutical company founded in 2002 that discovers, develops, and commercializes proprietary medicines for oncology, inflammation, autoimmunity, and dermatology; it operates globally in North America, Europe, and Asia with over 2,500 employees focused on unmet medical needs. The company markets a diversified portfolio of approved products including Jakafi (ruxolitinib) for myelofibrosis, polycythemia vera, and graft-versus-host disease; Opzelura (ruxolitinib) cream for atopic dermatitis and vitiligo; Pemazyre (pemigatinib) for cholangiocarcinoma and myeloid/lymphoid neoplasms; Monjuvi (tafasitamab-cxix) for relapsed or refractory diffuse large B-cell lymphoma; Tabrecta (capmatinib) for non-small cell lung cancer; Iclusig (ponatinib) for leukemia; and Olumiant (baricitinib) for rheumatoid arthritis and alopecia areata; it also advances a robust pipeline of clinical candidates discovered in-house targeting immunology, hematology-oncology, and inflammatory skin conditions. Recent developments include the 2024 acquisition of Escient Pharmaceuticals for $750 million to add first-in-class oral MRGPRX2 antagonists EP262 for hidradenitis suppurativa, prurigo nodularis, and other pruritic skin diseases and EP547 for pruritus in kidney and liver diseases; FDA approval of Niktimvo (axatilimab-csfr) with partner Syndax Pharmaceuticals in August 2024 for chronic graft-versus-host disease; relocation of over 300 Pennsylvania jobs to expanded downtown Wilmington headquarters by 2026 supporting more than 500 positions; and a 2025 roadmap featuring four potential product launches such as ruxolitinib XR and povorcitinib expansions, four pivotal trial readouts, seven proof-of-concept disclosures, and at least three Phase 3 initiations toward over 10 high-impact launches by 2030.
Chip Weakness, Middle East Concerns Drag Dow 549 Points
Incyte: I Am Moving From Hold To Buy
Incyte to Buy Vega Therapeutics in Hematology Deal Worth Up to $2B
Incyte Bets $1.25 Billion On Rare Bleeding Disorder Drug With Blockbuster Potential
Incyte Corporation (INCY) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Incyte Corporation (INCY) M&A Call Transcript
Here's Why Incyte (INCY) is a Strong Growth Stock
Incyte to Acquire Vega Therapeutics, a Wholly Owned Subsidiary of Star Therapeutics, Expanding its Hematology Portfolio into Bleeding Disorders
Incyte to Buy Vega Therapeutics For Up to $2 Billion
Incyte strikes up to $2 billion deal for Star Therapeutics' subsidiary
Incyte to Acquire Vega Therapeutics, a Wholly Owned Subsidiary of Star Therapeutics, Expanding its Hematology Portfolio into Bleeding Disorders
Incyte nears up to $2 billion deal for blood disorder biotech Star, FT reports
Mirum Pharmaceuticals and Incyte Announce Pivotal Late-Breaking Results for Zilurgisertib in Fibrodysplasia Ossificans Progressiva Accepted for Presentation at ENDO 2026
Mirum Pharmaceuticals and Incyte Announce Pivotal Late-Breaking Results for Zilurgisertib in Fibrodysplasia Ossificans Progressiva Accepted for Presentation at ENDO 2026
Incyte's Pivotal frontMIND Trial Showed Tafasitamab (Monjuvi®/Minjuvi®) Combination Significantly Prolonged Progression-free Survival, Reducing the Risk of Disease Progression or Death by 25% in Patie
Incyte blood cancer drug combo reduces disease-progression risk but with high side-effect rate
Incyte's Pivotal frontMIND Trial Showed Tafasitamab (Monjuvi®/Minjuvi®) Combination Significantly Prolonged Progression-free Survival, Reducing the Risk of Disease Progression or Death by 25% in Patients with Previously Untreated, High-risk DLBCL
Why Is Incyte (INCY) Down 1.8% Since Last Earnings Report?
Here's Why Incyte (INCY) is a Strong Momentum Stock
Incyte to Present at the Goldman Sachs 47th Annual Global Healthcare Conference